4-乙氧基-2-吡啶甲酸乙酯 | 71777-70-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-乙氧基-2-吡啶甲酸乙酯
• 英文名称: ethyl 4-ethoxypicolinate
• 英文别名: ethyl 4-ethoxypyridine-2-carboxylate
• CAS: 71777-70-3
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: LJXADWCGSBYCDC-UHFFFAOYSA-N

物化性质

• 密度：
  1.099

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  48.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-乙氧基-2-吡啶甲酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以99%的产率得到4-ethoxypicolinohydrazide
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS
  [FR] COMPOSÉS SUBSTITUÉS DE PYRIDINE EN TANT QUE MODULATEURS DE CRAC

  摘要：

  本发明涉及式(I)描述的化合物以及其中医药可接受的盐，这些化合物能够调节钙释放激活钙(CRAC)通道的活性。该发明还描述了式(I)的化合物以及包含这些化合物的药物组合物，用于治疗、管理和/或减轻与调节钙释放激活钙(CRAC)通道相关联的疾病、障碍、综合征或状况的严重性。

  公开号：

  WO2013164769A1
• 作为产物：
  描述：

  4-氯-吡啶-2-酰氯 、 乙醇 生成 4-乙氧基-2-吡啶甲酸乙酯
  参考文献：
  名称：

  IMPROVED PROCEDURES FOR PREPARATION OF 4-HYDROXY- AND 2-AMINO-4-METHOXY-2-AMINOPYRIDINES

  摘要：

  DOI：

  10.1080/00304949709355174

文献信息

• [EN] TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5 DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE
  申请人：CTXT PTY LTD

  公开号：WO2016034673A1

  公开（公告）日：2016-03-10

  A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式I的化合物，其中：n为1或2；p为0或1；R1可选地为一个或多个卤素或甲基基团；R2a和R2b分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别选自H和Me；R4为H或Me；R5为H或Me；R6a和R6b分别选自H和Me；A为(i)可选地取代的苯基；(ii)可选地取代的萘基；或(iii)可选地取代的C5-12杂环基。
• Use of metal complex compounds as catalysts for oxidation using molecular oxygen or air
  申请人：Wieprecht Torsten

  公开号：US20060019853A1

  公开（公告）日：2006-01-26

  Use, as a catalyst for oxidation reactions using molecular oxygen and/or air, of at least one metal complex compound of formula (1) wherein Me is manganese, titanium, iron, cobalt, nickel or copper, X is a coordinating or bridging radical, n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32, z is the charge of the metal complex, Y is a counter-ion, q=z/(charge of Y), and L is a ligand of formula (2) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are each independently of the others hydrogen; unsubstituted or substituted C 1 -C 18 alkyl or aryl; cyano; halogen; nitro; —COOR 12 or —SO 3 R 12 wherein R 12 is in each case hydrogen, a cation or unsubstituted or substituted C 1 -C 18 alkyl or aryl; —SR 13 , —SO 2 R 13 or —OR 13 wherein R 13 is in each case hydrogen or unsubstituted or substituted C 1 -C 18 alkyl or aryl; —NR 14 R 15 ; —(C 1 -C 6 alkylene)-NR 14 R 15 ; —N (+) R 14 R 15 R 16 ; —(C 1 -C 6 alkylene)-N (+) R 14 R 15 R 16 ; —N(R 13 )—(C 1 -C 6 alkylene)-NR 14 R 15 ; —N[(C 1 -C 6 alkylene)-NR 14 R 15 ] 2 ; —N(R 13 )—(C 1 -C 6 alkylene)-N (+) R 14 R 15 R 16 ; —N[(C 1 -C 6 alkylene)-N (+) R 14 R 15 R 16]2 ; —N(R 13 )—N—R 14 R 15 or —N(R 13 )N″R 14 R 15 R 16 , wherein R 13 is as defined above and R 14 , R 15 and R 16 are each independently of the other(s) hydrogen or unsubstituted or substituted C 1 -C 18 alkyl or aryl, or R 14 and R 15 , together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms. [L n Me m X p ] z Y q (1)

  使用至少一种具有以下式（1）的金属配合物化合物作为氧化反应的催化剂，其中Me为锰、钛、铁、钴、镍或铜，X为配位或桥联基团，n和m分别独立地为1至8之间的整数，p为0至32之间的整数，z为金属配合物的电荷，Y为对离子，q=z/(Y的电荷)，L为具有以下式（2）的配体，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11各自独立地为氢；未取代或取代的C1-C18烷基或芳基；氰基；卤素；硝基；—COOR12或—SO3R12，其中R12在每种情况下为氢、阳离子或未取代或取代的C1-C18烷基或芳基；—SR13、—SO2R13或—OR13，其中R13在每种情况下为氢或未取代或取代的C1-C18烷基或芳基；—NR14R15；—(C1-C6烷基)-NR14R15；—N(+)R14R15R16；—(C1-C6烷基)-N(+)R14R15R16；—N(R13)—(C1-C6烷基)-NR14R15；—N[(C1-C6烷基)-NR14R15]2；—N(R13)—(C1-C6烷基)-N(+)R14R15R16；—N[(C1-C6烷基)-N(+)R14R15R16]2；—N(R13)—N—R14R15或—N(R13)N″R14R15R16，其中R13如上定义，R14、R15和R16各自独立地为氢或未取代或取代的C1-C18烷基或芳基，或R14和R15与连接它们的氮原子一起形成未取代或取代的5、6或7成员环，该环可能含有进一步的杂原子。[LnMemXp]zYq（1）
• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281396A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer as well as sepsis, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防癌症以及败血症，包括NUT中线癌、Burkitt淋巴瘤、急性髓样白血病和多发性骨髓瘤。
• Use of metal complex compounds as oxidation catalysts
  申请人：——

  公开号：US20040142843A1

  公开（公告）日：2004-07-22

  Use of metal complex compounds of formula (1): [L n Me m X p ] z Y q wherein Me is manganese, titanium, iron, cobalt, nickel or copper, X is a coordinating or bridging radical, n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32, z is the charge of the metal complex, y is a counter-ion, q=z/(charge Y), and L is a ligand of formula (2) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are each independently of the others hydrogen; unsubstituted or substituted C 1 -C 18 alkyl or aryl; cyano; halogen; nitro; —COOR 12 or —SO 3 R 12 wherein R 12 is in each case hydrogen, a cation or unsubstituted or substituted C 1 -C 18 alkyl or aryl; —SR 13 , —OR 13 or —OR 13 wherein R 13 is in each case hydrogen or unsubstituted or substituted C 1 -C 18 alkyl or aryl; —N(R 13 )—NR′ 13 R″ 13 wherein R 13 , R′ 13 and R″ 13 are as defined above for R 13 ; —NR 14 R 15 or —N + R 14 R 15 R 16 wherein R 14 , R 15 and R 16 are each independently of the other(s) hydrogen or unsubstituted or substituted C 1 -C 18 alkyl or aryl, or R 14 and R 15 together with the nitrogen atom bonding them form an unsubstituted or substituted 5 -, 6 - or 7 -membered ring which may optionally contain further hetero atoms; with the proviso that R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are not simultaneously hydrogen, as catalysts for oxidation reactions, and the novel metal complex compounds of formula (1) and the novel ligands of formula (2). 1

  使用公式（1）的金属配合物化合物：[LnMemXp]zYq，其中Me是锰、钛、铁、钴、镍或铜，X是配位或桥联基团，n和m分别独立地为1至8的整数，p为0至32的整数，z是金属配合物的电荷，y是反离子，q=z/（反离子Y的电荷），L是公式（2）的配体，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11各自独立地为氢；未取代或取代的C1-C18烷基或芳基；氰基；卤素；硝基；—COOR12或—SO3R12，其中R12在每种情况下为氢、阳离子或未取代或取代的C1-C18烷基或芳基；—SR13、—OR13或—OR13，其中R13在每种情况下为氢或未取代或取代的C1-C18烷基或芳基；—N（R13）—NR'13R"13，其中R13、R'13和R"13如上所定义为R13；—NR14R15或—N+R14R15R16，其中R14、R15和R16各自独立地为氢或未取代或取代的C1-C18烷基或芳基，或者R14和R15与其结合的氮原子形成未取代或取代的5-、6-或7-成员环，该环可以选择性地包含进一步的杂原子；但是，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10和R11不能同时为氢，作为氧化反应的催化剂，以及公式（1）的新金属配合物化合物和公式（2）的新配体。
• Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
  申请人：Wong C.W. Norman

  公开号：US20060205767A1

  公开（公告）日：2006-09-14

  The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.

  本公开提供了非自然产生的多酚化合物，其可上调载脂蛋白A-I（ApoA-I）的表达。所公开的组合物和方法可用于治疗和预防心血管疾病及相关疾病状态，包括胆固醇或脂质相关障碍，例如动脉粥样硬化等。